Summit Therapeutics SMMT

Summit Therapeutics Inc. · Nasdaq · Pharmaceutical Preparations

$9.95-5.87%close on Nov. 20, 2026 · volume 7.2M · Yahoo Finance

Price, last 64 sessions

$10.00$12.50$15.00$17.50Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 20, 2026 · high $18.42 · low $9.95 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

Recent SEC filings

All 17 →
  • 4Nov. 20, 2026, 6:22 p.m. ETView on SEC.gov
  • 4Nov. 20, 2026, 6:26 p.m. ETView on SEC.gov
  • 8-KNov. 18, 2026, 8:16 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

    AI summary, unreviewedSummit Therapeutics Announces Planned Phase III HARMONi-10 Trial of Ivonescimab vs Durvalumab in Stage III NSCLC

  • 8-KNov. 16, 2026, 6:08 a.m. ETView on SEC.govOur explainer

    Other events · Financial statements and exhibits

    AI summary, unreviewedSummit Therapeutics Receives FDA Complete Response Letter for Ivonescimab BLA in Second-Line EGFR-Mutated NSCLC, Citing Lack of Statistically Significant Overall Survival Benefit

  • 4Nov. 16, 2026, 7:49 p.m. ETView on SEC.gov
  • 4Nov. 16, 2026, 8:23 p.m. ETView on SEC.gov
  • 4Nov. 16, 2026, 8:26 p.m. ETView on SEC.gov
  • 10-QNov. 4, 2026, 5:08 p.m. ETView on SEC.gov